are you playing the drop below the lower daily bollinger today then at 30.50 it would be back just inside it tomorrow on the daily? and correct the rsi oversold levels on the intra-days at the same time
Printable View
To me it appears to have quite clearly broken down below the right shoulder and is headed lower. Left shoulder was at ~ $33.50 in early April, right shoulder was broken just recently.
Quite apart from the H&S pattern which in itself is a clear TA warning, there's a clear breakdown through the 100 day MA at $32.50 recently and its now broken down though the 200day MA which I understand is widely used by technicians as absolute confirmation of a trend change.
My assessment is the FPH has enjoyed a VERY strong run on the back of Covid and its starting to break down with uncertain forward fundamentals and very concerning looking technical's.
Others will have a different view and some may even be emotionally wed to it because of stellar past returns and that's fine and good luck to them.
Disc: No financial interest in FPH, either long or short.
being to greedy on these trades caught me out plenty of times.
anyway ive eaten thru half pack of superwines watching the slow grind back to 30.50 lol.
on a larger time frame i have a big trading range between 36.50 to 28 so buying around 28 had this to support your decision as well
You're welcome mate. You can see the head and shoulders pattern really clearly in the NBR chart image to the right of this article here https://www.nbr.co.nz/story/analysts...ly-weigh-stock
Hey alokdhir
Do your numbers give any idea what Q1 sales will be like. If it’s any help Gradon says ‘ the first quarter of the current year could be similar to the final quarter of the 2021 financial year.“
Was the final quarter 2021 better than the first quarter 2021 ...ie 2022 of to a good start
He’s pissed many off by no even giving a hint as to what 2022 is going to be like. This implies he is comfortable with analyst forecasts of a 25% decline in earnings. There is disclosure ‘issues’ if company and market expectations are miles apart.
A 2022 eps of 70 cents not much for a 30 buck share
Hey Winner, bit of commentary in here about final quarter FY21 sales and how they were below market expectations https://www.goodreturns.co.nz/articl...or+27+May+2021
Hope that helps.
Still a great business. I first bought it well below $5 years ago and the high NZD was a barrier. Everyone thought it was over priced but time went by and it became less affected by the high NZD. Then the NZD went into decline and sleep apnea sales took off. Share price takes off too. It is over priced short term but being a great business its time will come again. Absolutely no doubt.
I have already written about April sales from latest Stat NZ data ...April revenue up 51% PCP ...it translates to $ 163 mil revenue ...thats all data I have at the moment .
Last qtr of FY 21 was almost same as first qtr of FY 21 ....but April 21 data seems better then Jan, Feb or March ... So from April data we can see FY 22 off to good start with 51% increase in April 21 PCP basis ...this translates to 1.96B revenue ...163 mil per month basis
just a month to look at ....so not much to go on . U need to take a call on Covid situation long term as their revenues are directly related to covid hospitalisations
He has also mentioned Covid endemic hospitalisations ...after pandemic over ...hinting at long term benefit here . Also mentioned home care ventilation boosts tracking covid hospitalisations ....also hinting at new area of non hospital revenues then pre covid which was basically sleep clinics related home care products
Overall pre covid they were growing at 10% revenue and 15-18% NPAT ...still it was boosting SP by 20-30 % PA ...so now they grew 60% and 80% NPAT which is basically 4 years of organic growth at pre covid rates but SP now is just 35% over pre covid levels . Thats PE contraction as market not sure about immediate future . I still think keeping in view the quality of the company and its niche area ...market will eventually bring it to forward PE of 50 as before . Let the dust settle
Same reaction was seen on the results day of its peer company RMD listed on NYSE ...it went down 13% ...then slowly its back !!
FPH quality of management and products are world class ...they will catch up with old trend in next 1-2 years max .
Next week in 3 web based investor days FPH will enlighten the investors and analysts about its bright future and progress made during pandemic opportunities .
Hopefully market will like what they want to show !!
IMHO FY 22 eps will most likely end up between 0.70 to 0.80 cents ...provided nothing big changes on Covid front ...this qtr is panning out to be like 1st qtr or 4th qtr ( both were almost same ) of FY 21 ....
If you play around with FPH sales numbers over the year and what they said in updates I reckon Q421 sales were about 390m. Gardon sort of said Q122 sales would be in line with this so maybe 400m - this I reckon is 15% down on H121. Bit spooky that when analysts are expecting 15% decline for full year
Be interesting to see what eventuates
Share price on fire today - that's good
As company will not provide guidance and uncertainty around covid which effects its revenues in big way ....FPH will remain volatile but rangebound ....like Bull said ...36.50 to 27.50 . Company should have agreed to provide quarterly trading updates ( I think they may do that ) So they may give first announcement about how FY 22 panning out by July last week . Till then it will remain here only ...28-32
Craigs
March quarter surprisingly soft
With fwd PE still 43x FY22e we maintain Neutral with revised $33.89 TP
whats scary to me is how far out the Craigs analysis goes without any significant increase in yield or reduction in multiple.
in three years time you'll still be getting less than 2% return and on a PE of over 40.
After analysing revenue trend data from Jan 2021 onwards ...estimated following numbers ....Jan = $ 125 M ( + 44% PCP ) Feb = $ 120 M ( + 15 ) March = $ 155 M ( + 6 ) April = $ 165 ( + 51 )
Also seeing the infections data of top 10 most vaccinated countries ....Covid is still managing to put people in hospitals ...especially UAE and Chile ( Top vaccinated)
So its too early to write off Covid effect or boost to FPH ...IMHO
Almost all analysts have been quick to downgrade it to Hold with consensus target of $ 32.50 ( Original Forbar's )
That makes it the dark horse now ...if they get a quarter like 3rd qtr of FY 21 then all will be jumping to upgrade . Think 3rd qtr ....UK and USA stocked big time !!
Longterm holders need hold ...things can change for better suddenly too ...uncertainty of Covid cuts both ways .
Underperform is the current trend surely
Aging population(s) will continue to drive some demand for their products.
Particularly in America where people are living longer but certaintely not healthier.
Can't see Covid going anywhere any time soon, the majority of the world is only now starting to experience its highest cases.
Heavily vaccinated countries have a huge number of waiting patients, many believe this will be the new crisis as large numbers of ill and poorly people start going back to their GP and hospitals.
New rare diseases have been found showing up in recovered patients affecting the lungs, lots of long term issues needed assistants from respiratory devices.
Lots of countries will start to restock and store medical equipment?
I'm new to this game but look what happened with ATM and their guidance, how many times did they have to change to a downgrade, all due to uncertainty with covid, trade and shipments, sure some other factors also, maybe someone could tell me FPH may be trying to play it safe in uncertain times? It seems people believe the world has recovered or is recovering but it's still as much a disaster as it was when all of this kicked off
Have you got any references to back that? What I have seen is that the USA is quite low down in the list of life expectancy for developed countries. Perhaps it is because there is a vastly different outcome for Americans depending on wealth - with wealthier Americans living longer, healthier and with access to cutting edge healthcare.
List of countries by life expectancy
en.wikipedia.org/wiki/List_of_countries_by_life_expectancy#List_by_the_W orld_Health_Organization_(2019)
Interesting links. With advancing health treatments, the health conditions that people face has changed over time. This is an issue facing other countries in addition to the USA. Unequal access to health services has an effect too.
https://www.telegraph.co.uk/news/201...g-poor-health/
http://nzx-prod-s7fsd7f98s.s3-websit...173/347408.pdf
todays presentation extremely medically oriented despite being for investors and analysts....
of course its their specialty but not for me to read.
however they do map out their short medium and long term objectives though its all a bit unconvincing.
that 12% revenue growth projection seems a bit achievable.
I know nothing other than that management of FPH are top notch and tend to under promise and over deliver
12% growth projection is far higher than many analysts have arrived at. Analysts are projecting a drop off after covid.
https://www.marketscreener.com/quote...30/financials/
I am reasonably confident of which ones have a better understanding of the business
In a post-vaccinated world, COVID-19 may well continue to spread, but overall the physiological impact will be much less than we're seeing today. The unvaccinated, the long-haul sufferers and other similar groups will still require the types of products that FPH produce, but demand shouldn't continue to grow at the same rate is has in the past.
For those that don't wish to read through entire presentations
FPH have short(Hospital respiratory support), medium(Home respiratory support) and long term (Surgical technologies) growth covered
pg 5-7 investor series
https://www.fphcare.com/nz/our-compa...estor/reports/
Future is bright for FPH ...but short term uncertainty will make the stock underperform . Medium to long term exceptionally positive .
From 10% revenue growth target has been upgraded to 12 % ...thats how positive management is feeling after this covid exposure on the world stage .
I am sure many smarter analysts will also take note of brighter future ahead ...consensus 0.62 cents eps is too pessimistic IMHO ...more like between 0.70-0.80 range depending upon how covid behaves ahead . So Craigs target of around $ 34 seems very realistic with upside surprise possibly .
FPH SP needs time to settle down ....last August it was $ 38 in expectations of these results which just revealed ....now its $ 29 in anticipation of sales falling fully !
In the bigger scenario current calendar is small up or down movement only ...30- 35 . Look for it in calendar 22 and 23 .
case in point:
https://www.nzherald.co.nz/entertain...5N7XEQ3EIMRNU/
Respiratory device spotted with simon cowell.
Good to see Michael Daniell get knighted
Kiwi ventilator manufacturer F&P Healthcare led the market higher, leaping 5.6% to $30.75, with investors trading almost $30 million worth of stock.
Hamilton Hindin Greene investment adviser, Grant Davies said the move was likely driven by the news that Royal Phillips – better known just as Phillips – had recalled 4 million to 5m ventilators and sleep apnoea devices.
The Dutch company found possible health risks with a polyester-based foam used for sound absorption in the products. This sent its share price tumbling more than 4% and shaved a billion dollars off its market capitalisation.
Some of this money seemed to find its way to competitor firms, with healthcare company ResMed also jumping 6% on the ASX today.
https://www.goodreturns.co.nz/articl...-products.html
With new developments about big product recall by number 2 sleep apnea device maker Philips thus taking them out of the market for next 18 months as indicated by their own spokesperson ...also said will lead to shortage of devices in the short term . This gives number 3 manufacturer FPH a great chance to boost its market share in Homecare segment . Its very possible they maybe able to win extra $ 200 million sales in this segment which will help cover majority of the hospital division shortfall for the current year IMHO ...Makes holding FPH even more interesting as knowing the management ...they will surely try to cash on this opportunity fully ..their weaker segment Home Care . RMD has 43% market share Philips 31% and FPH 12% ...with Philips out for medium term plus the damage this recall will do to their reputation ....hopefully FPH should capitalise big .
Resmed share price shot up on the news... sign of things to come for FPH?
Resmed up 10% during last 5 days, 23% for the month.
here we go again!
https://www.nzherald.co.nz/world/cov...CLN2GGG6FE3BQ/
Nice SP action recently.....
Onwards and upwards.
May exports data out today . Estimated revenue for FPH comes to $ 179 mil UP 13% PCP
Now we have 2 months for FY 22 which seems to be holding up better then expected ...163 , 179 mil for April and May revenues
Good.
However - it still might be a bit early to praise the year after the first two months of revenue. Whatever is happening currently in the world - linear extrapolation might not be the best method to forecast the future :):
Discl: holding a wee parcel and don't mind to buy more if the price is right.
From FN Arena: https://www.fnarena.com/index.php/20...n-28-2021/#FPH
FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
Medical Equipment & Devices – Overnight Price: $29.31
Goldman Sachs rates ((FPH)) as Buy (1) –
Beyond some near-term dynamics, including the decline in hospitalisations and elevated air freight costs, Goldman Sachs discerns nothing changes the broker's positive mid/long-term view on Fisher & Paykel Healthcare.
Overall, Goldman Sachs updates sales, earnings, and earnings per share forecasts by an average of -8%, -18%, and -18% through FY22-23 as the broker re-bases consumables forecasts to reflect a lower exit-rate and factor in an elevated level of air freight costs.
The broker's FY22-25 earnings forecasts are 4-12% above their pre-pandemic levels.
Although not cheap in absolute terms, Goldman Sachs sees a clear double-digit growth trajectory plus, on a growth-adjusted basis, more valuation support than for other manufacturers.
Buy rating is maintained. Target price is lowered to $33.00 to reflect earnings revisions.
This report was produced on May 27, 2021.
Target price is $33.00 Current Price is $29.31 Difference: $3.69
If FPH meets the Goldman Sachs target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $30.00, suggesting upside of 2.4%(ex-dividends)
The company's fiscal year ends in March.
Forecast for FY22:
Goldman Sachs forecasts a full year FY22 dividend of 37.23 cents and EPS of 53.05 cents.
At the last closing share price the estimated dividend yield is 1.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 55.25.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.1, implying annual growth of N/A.
Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 47.2.
Forecast for FY23:
Goldman Sachs forecasts a full year FY23 dividend of 43.75 cents and EPS of 62.36 cents.
At the last closing share price the estimated dividend yield is 1.49%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 47.00.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.8, implying annual growth of 1.1%.
Current consensus DPS estimate is 40.7, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 46.7.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((FPH)) as Overweight (2) –
Fisher & Paykel Healthcare has reported a strong FY21 result, with net profit up 82% to NZ$524m, but soft relative to high market expectations, according to Jarden.
The step change in profitability was underpinned by unprecedented covid demand for its hospital division, with the company selling around 6x normal hardware, and circa 2x consumables, while treating 20m patients.
No earnings guidance was provided for FY22, but the company reiterated its NZ$20bn total addressable market estimate. The company also reaffirmed plans to keep advancing manufacturing capacity and hold higher levels of inventory to ensure any surge in demand can be met.
The broker believes covid has materially strengthened the company's growth opportunity, particularly with respect to high nasal flow therapy both with the Hospital and Home setting.
Jarden has amended FY22-24 net profit estimates by -4%, -4%, and 1% but notes the inherent difficulty calibrating what a normalisation profile looks like for the company.
Overweight recommendation maintained, and target price is lowered to NZ$34.00 from NZ$36.10 to reflect Jarden's near-term downgraded forecasts.
The report was issued May 27, 2021.
Current Price is $29.31. Target price not assessed.
Current consensus price target is $30.00, suggesting upside of 2.4%(ex-dividends)
The company's fiscal year ends in March.
Forecast for FY22:
Jarden forecasts a full year FY22 dividend of 42.54 cents and EPS of 65.43 cents.
At the last closing share price the estimated dividend yield is 1.45%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 44.79.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.1, implying annual growth of N/A.
Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 47.2.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 48.59 cents and EPS of 74.65 cents.
At the last closing share price the estimated dividend yield is 1.66%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 39.27.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.8, implying annual growth of 1.1%.
Current consensus DPS estimate is 40.7, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 46.7.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Wilsons rates ((FPH)) as Overweight (1) –
While short term earnings visibility remains tough in the absence of quantitative guidance, Wilsons' positive view on Fisher & Paykel Healthcare is based on the broker's analysis of the outlook for the company's high-flow nasal cannula device.
The company's second half result featured a beat on hardware sales, and this momentum will likely continue in emerging markets where covid admissions remain high, the broker suggests.
Consumables sales missed the broker's forecasts but it is impossible to determine whether this reflects a lag in installed base ‘pull-through’ or suboptimal utilisation of units placed during the pandemic, the broker notes.
Overweight retained, target falls to $35.00 from $37.50.
Report first published May 28, 2021.
Target price is $35.00 Current Price is $29.31 Difference: $5.69
If FPH meets the Wilsons target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $30.00, suggesting upside of 2.4%(ex-dividends)
The company's fiscal year ends in March.
Forecast for FY22:
Wilsons forecasts a full year FY22 dividend of 37.23 cents and EPS of 64.78 cents.
At the last closing share price the estimated dividend yield is 1.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 45.25.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.1, implying annual growth of N/A.
Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 47.2.
Forecast for FY23:
Wilsons forecasts a full year FY23 dividend of 38.16 cents and EPS of 66.27 cents.
At the last closing share price the estimated dividend yield is 1.30%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 44.23.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.8, implying annual growth of 1.1%.
Current consensus DPS estimate is 40.7, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 46.7.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Thanks for posting Kiwiyankee.
"clear double-digit growth trajectory"
"covid has materially strengthened the company's growth opportunity, particularly with respect to high nasal flow therapy both with the Hospital and Home setting."
Brokers all got their estimates wrong. I won't bother. Happy to keep buying on any share price weakness, around $29 seems to be working. Has popped down there a few times then bounced back to the low $30's.
Hold for long long term. Can't go wrong? Don't think ill regret holding these come 2030.. 2040
With more and more countries realising that Covid is here to stay like Australia ....Future for FPH becomes brighter then what analysts at present forecasting ....
IMHO FPH will be main driver of our market ahead ...even revenue data indicators are pointing towards much better outcome for full year then presently discounted by market . Now it will have some boost from home care side business also due to Philips's woes .
Its very feasible that FPH exceeds last years revenue rather then 30% drop market anticipating at the moment . Its buy the dips now strategy
Covid will always be here, we have just got to live with it. ie like the flu and other viruses. Vaccines are here like the flu jab and hospitals have their tools to help patients. There will always be demand for FPH product, just to what degree that influences their product sales
Didnt say they did, but they do sell plenty of items that hospitals world wide have used effectively to fight Covid and other health issues.
Yes, but that was due to there being no vaccine. Now there is a vaccine, rich countries that can afford FPH products will eventually be fully vaccinated to the point they do not have significant covid hospitalization. Not that I think FPH hasn't got a great future, I'm holding and currently adding. They are a great company.
Spent a quiet Sunday reading NBR's Shoeshine Feb column on NBR. Seems that apart from For/Bar there are many who disagree that the end of Covid will see a drop in demand for FPH's products.
- FPH have a track record of under-promising and over-delivering
- FPH would not have invested so much $mill in new plant expansion if they were bearish
- FPH's key products in breathing/ventilation assistance have proven their worth in Covid times and their usefulness has now expanded into other areas where FPH is now part of 'normal operating procedures' for treatment of emphysema, other respiratory issues and even 'long covid' etc etc.
Interesting times ahead for holders IMHO.
Fully agree and also no need to try to convert non believers ...Covid boost or covid income is just a bonus for FPH . Covid also gave FPH enormous positive publicity and goodwill of so many doctors and hospital purchasers that they will thank covid for years to come .
Even in 2019 they were planning to double their production of hospital equipment by 2023 . They had so much confidence in their therapies and devices
Holding FPH for next 3-5 years is going to be best and safest call IMHO .
Got my buy order in at $29 just in case it falls back there for a bit.
Agree next 3, 5, 10… yrs it’s a compelling hold
Covid here for the long term..... even for 'our lifetime'.... according to this article .
There was this guy on the radio last night saying his business has seen activity fall away quite a lot over the last month which surprised him a bit because over the last year he had been flat out. Said he used to get three to four big orders a month but now it’s down to one if he’s lucky …….he said he makes components for Fisher and Paykel.
I assumed he was talking about FPH because he added in some respects that’s good because it means less people are dying
BlackRock keen to up their holding?
Interesting. I genuinely wonder if having Blackrock as a major shareholder is a double edged sword. Having looked at the various meme short squeeze stocks over the past few months, a common factor I am seeing is Blackrock. They are willing buyers using other people's money in their funds, but I also believe they are an equally willing lender of shares to hedge funds for shorting, for the benefit of Blackrock. Who would lend out shares to shorters, unless you didn't actually own them for your own benefit? It must be the funds & institutions.
As the short squeeze plays out and dies down, it is often Blackrock whose shareholding also dies down over that time frame as short positions and synthetic shares unwind. This is purely anecdotal observations on my part rather than hard and fast data where historically Blackrock has been a major (sometimes the largest) shareholder in shares that have been subjected to attempted short squeezes. I'm not suggesting this is about to happen with FPH, although I do note the current short interest in FPH on the ASX is around 0.5% (not high) and has been on a general uptrend for the past 24 months.
I'm with you on this. What I see is short term shorting on a stock and algorithm trading which lowers the SP and drives out small investors, while the big institutions load up.
I recall the days when XRO went from $40 down to $13 and of course ATM's current slide $20 to $6 is partially big investors taking advantage of the profit downgrades.
As a long term small investor I'm not too worried as good companies bounce back, (he said hopefully.) I still see FPH as a $50 share in 2 yrs....and remember small investors can benefit, as long as we have the intestinal fortitude (guts) to buy on the lows.
Black Rock also loaded up on AIA
Good week for holders.
On the leaderboard and up $1 today. Naice.
Overseas Merchandise data June
Breathing apparatus exports appear to have declined v last year
Are you sure W?
Optical, medical, and measuring equipment 120 99 -16.9 333 374 12.3
1,153 (2020) 1,624 (2021) 40.8 %
Overall up 40%?
Were is breathing equipment specifically listed?
I just saw this diagram in Stats report
https://www.stats.govt.nz/informatio...rade-june-2021
Ack thanks
So breathing equipment could be up as I couldn't specifically find it listed separate from optical, medical & measuring?
Not sure how to make the image bigger but I think you are both right. June month is down 17% but June year is up 40%.
Attachment 12778
we need alokdhir to give us the real numbers - he keep tracks of exports at a lower level
Do we know how much of FPH's production is made in NZ - and exported - and how much is made overseas?
So much guessing and second guessing of how much top line and bottom line will slip from the covid bump we had FY21. I think KFL summed it up well in their latest update on how to approach this.
It's trading at 35 P/E and could comfortably trade at a 50 P/E like other blue chip medical companies. So room to absorb a pull back from FY21 bumper numbers (if any).Quote:
We bought Fisher & Paykel Healthcare when the marketover-reacted to negative newsFisher & Paykel Healthcare’s Optiflow technology became the globalstandard for treating COVID last year. Demand for Optiflow surged.However, for the last 15 months, the market has been desperatelytrying to pre-empt and price the end of that surge. The market thought itsaw the end of the surge in May, when the company delivered weakerthan-expected results, and an uncertain short-term outlook saw the shareprice fall by 15%.To us, a key attraction of the company is its exceptionally long runwayfor growth. Around 50 million acute respiratory-illness patients a yearwould benefit from the Optiflow product. With Optiflow currentlytreating less than 10 million patients, we believe there is capacityto serve more. Investors who focus on the short-term, post-COVIDslowdown in demand, may end up limiting their potential participationin this forecast runway for growth.We bought more Fisher & Paykel Healthcare stock when the market’sknee-jerk reaction to short-term noise made the price attractive.
Just stating as I see the data ....Its varying a lot month on month basis ...so not easy to extrapolate anything ....overall they will do well on two counts
1. Covid will keep giving them long term business in addition to their standard bread and butter business
2 . They will most likely get a boost to Sleep apnea devices business also after Philips No 2 provider goes offline for next 18 months to service recalled devices
So I am still hopeful that they may end up doing almost similar revenues like last year ...
FPH were investing in new manufacturing facilities due to covid. I wonder if this was in NZ or outside? maybe more in Mexico?
Their new factories 2 in Mexico and 1 in Auckland were planned much before Covid came but they hastened their commissioning ....One still getting ready in Mexico ...2022 is the earliest it come online
They planned to almost double their Hospital sector capacity by 2023 ( Was planned in 2018 ) and 60% to Homecare sector capacity .
This was done after seeing the performance and acceptance of its new products like Optiflow and Airvo2 etc
By 2024 they plan to have $ 3.5-4 Billion in revenue ...so if it works out well then FPH maybe $ 75 in 2024 !!!
Thanks alokdhir- share traders 'FPH master'
Delta variant gradually becoming more of an issue, vaccinated people now being asked to wear masks in the US.
Plus vaccine hesitancy and subsequent outbreaks, may lead to a more sales which analysts haven't really priced in.
https://www.usnews.com/news/best-sta...cination-rates
This graph highlights the concerning recent trend in the USA..... heading back to over 100,000 cases per day.
Attachment 12806
Unfortunately that too are rising fast currently at 94600 critical and almost 5 times in hospital . Though its well established that vaccinations have helped reduce severe symptoms .
Only worry is waning immunity of vaccines and new variants emerging .
Its a long term story which all have started realising sadly .
https://www.worldometers.info/coronavirus/
At last peak ...Critical patients topped out at 110,000 ....now we are getting close as Delta takes full hold ...maybe peak about 2 weeks away on global front .
That is 16 m that have had it & not died or recovered?
https://www.worldometers.info/coronavirus/
Ventilators and high flow machines in demand again:
https://www.youtube.com/watch?v=eAftL31o-8A
New cases +235k per day.
Texas seeking out of state help now, which may include more ventilators.
https://www.latimes.com/world-nation...d-covid-crisis
https://www.bloomberg.com/news/articles/2021-08-08/austin-with-just-six-icu-beds-left-warns-of-dire-covid-state
Scary stuff. Why did the scare price tank 1.15 today? Concerns over growth in the quarterly report due soon???
I recall reading a brokers commentary that said FPH often has big(ish) swings depending on what the offshore funds were doing.
Certainly hasn’t tanked.
Down again today …in the NZ Herald -
Matt Goodson, managing director of Salts Fund Management, said the market was mixed and led down by Fisher and Paykel Healthcare, which has been weak over the past two days.
"The only thing I can connect this with is the result from an American medical devices company Vapotherm which suggested sales looking forward were falling away quicker than expected.